EUVIMEDEUVIMED entdecken
Open Access · CC0

Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua

Federico Narvaez, Carlos Montenegro, Jose G Juarez, José Victor Zambrana, Karla Gonzalez, Elsa Videa, Sonia Arguello, Fanny Barrios, Sergio Ojeda, Miguel Plazaola, Nery Sanchez, Daniel Camprubí-Ferrer und 4 weitere

PLOS Neglected Tropical Diseases · 10.01.2025 · 19 (1) · e0012811

DOI: 10.1371/journal.pntd.0012811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 10.01.2025. Verfasst von Federico Narvaez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Infectología, Hospital Infantil Manuel de Jesús Rivera, Ministerio de Salud, Managua, Nicaragua. Hauptthemen laut MEDLINE: Dengue Virus, Dengue. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, National Institutes of Health, International AIDS Vaccine Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dengue virus, a major global health threat, consists of four serotypes (DENV1-4) that cause a range of clinical manifestations from mild to severe and potentially fatal disease.

Methods

This study, based on 19 years of data from the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study in Managua, Nicaragua, investigates the relationship of serotype and immune status with dengue severity. Dengue cases were confirmed by molecular, serological, and/or virological methods, and study participants 6 months to 17 years old were followed during their hospital stay or as ambulatory patients.

Results

We enrolled a total of 15,833 participants, of whom 3,308 (21%) were positive for DENV infection. Of 2,644 cases with serotype result by RT-PCR, 559 corresponded to DENV1, 1,002 to DENV2, 760 to DENV3 and 323 to DENV4. Severe disease was more prevalent among secondary DENV2 and DENV4 cases, while similar disease severity was observed in both primary and secondary DENV1 and DENV3 cases. According to the 1997 World Health Organization (WHO) severity classification, both DENV2 and DENV3 caused a higher proportion of severe disease compared to other serotypes, whereas DENV3 caused the greatest percentage of severity according to the WHO-2009 classification. DENV2 was associated with increased odds of pleural effusion and low platelet count, while DENV3 was associated with both hypotensive and compensated shock.

Conclusions

These findings demonstrate differences in dengue severity by serotype and immune status and emphasize the critical need for a dengue vaccine with balanced effectiveness against all four serotypes, particularly as existing vaccines show variable efficacy by serotype and serostatus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VirusDengueHumansNicaraguaChildAdolescentSerogroupChild, PreschoolFemaleMaleInfantSeverity of Illness IndexAntibodies, ViralCohort Studies

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Unidad de Infectología, Hospital Infantil Manuel de Jesús Rivera, Ministerio de Salud, Managua, Nicaragua.
  • Sustainable Sciences Institute, Managua, Nicaragua.
  • Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua.
  • Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, San Juan, Puerto Rico.
  • Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua.

ORCID-Profile: Angel Balmaseda

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • International AIDS Vaccine Initiative
  • Bill and Melinda Gates Foundation

Zitieren

APA

Narvaez, F., Montenegro, C., Juarez, J. G., Zambrana, J. V., Gonzalez, K., Videa, E., Arguello, S., Barrios, F., Ojeda, S., Plazaola, M., Sanchez, N., Camprubí-Ferrer, D., Kuan, G., Paz Bailey, G., Harris, E., & Balmaseda, A. (2025). Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua. PLOS Neglected Tropical Diseases, 19(1), e0012811. https://doi.org/10.1371/journal.pntd.0012811

Vancouver

Narvaez F, Montenegro C, Juarez JG, Zambrana JV, Gonzalez K, Videa E, et al. Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua. PLOS Neglected Tropical Diseases. 2025;19(1):e0012811. doi:10.1371/journal.pntd.0012811

BibTeX
@article{Narvaez2025,
  author = {Narvaez, Federico and Montenegro, Carlos and Juarez, Jose G and Zambrana, José Victor and Gonzalez, Karla and Videa, Elsa and Arguello, Sonia and Barrios, Fanny and Ojeda, Sergio and Plazaola, Miguel and Sanchez, Nery and Camprubí-Ferrer, Daniel and Kuan, Guillermina and Paz Bailey, Gabriela and Harris, Eva and Balmaseda, Angel},
  title = {Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  volume = {19},
  number = {1},
  pages = {e0012811},
  doi = {10.1371/journal.pntd.0012811}
}
Kostenlos starten →